Mobile website
Archive > Volume 22 Issue 4 > 2015,22(4):413-419. DOI:10.3872/j.issn.1007-385X.2015.04.001 Prev Next
Expert Forum
The efficacy evaluation criteria for targeted therapeutics in solid tumors：Current status and prospective
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
In recent years, the breakthroughs of targeting agents for tumor therapies and personalized molecular diagnosis have prompted cancer treatment into the era of precision medicine. However, established assessment for solid tumors treatment such as the WHO or RECIST evaluation criteria could not reflex precisely the efficacy of the targeted therapeutics and the survival benefits they provided to patients. Therefore, it is extremely urgent to explore and establish a new response assessment criteria for targeted tumor therapeutics. This article reviewed the history of the efficacy assessment criteria for anti-tumor drugs and current opinions on the subject. I also introduced the evolution and development of evaluation criteria for various targeted therapeutics toward different tumors, and focused on the new criteria for evaluating immuno-related therapeutics. Finally, I discussed in detail the proposed evaluation criteria, its definition, guiding principle and clinical application. It is conceivable that the continuous improvements in evaluating targeted therapeutics for solid tumors will bring transformation to personalized cancer treatment.
Keywords:
Project Supported:
Project supported by the National Program for High Technology Research and Development of China (863 Program) (No. 2012AA02A204), the National Natural Science Foundation of China (No. 81160245), and the Science and Technology Planning Project of Yunnan Province, China (No. 2011FB160)
Clc Number:
